Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dersimelagon - Mitsubishi Tanabe Pharma

X
Drug Profile

Dersimelagon - Mitsubishi Tanabe Pharma

Alternative Names: [14C] MT-7117; Dersimelagon; MT-7117; MT-7117-MB

Latest Information Update: 21 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Class Carboxylic acids; Cyclopentanes; Fluorinated hydrocarbons; Phenyl ethers; Piperidines; Pyrrolidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Melanocortin type 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Erythropoietic protoporphyria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Erythropoietic protoporphyria
  • Phase II Diffuse scleroderma
  • No development reported Autoimmune disorders

Most Recent Events

  • 14 Feb 2024 Mitsubishi Tanabe Pharma America completes a phase II trial in Diffuse scleroderma (In the elderly, In adults) in USA, Belgium, Canada, Germany, Italy, Spain, Poland and the United Kingdom (PO) (NCT04440592) (EudraCT2020-000134-17)
  • 11 Dec 2023 Phase-III clinical trials in Erythropoietic protoporphyria (In adolescents, In adults, In the elderly) in USA (PO) (NCT06144840)
  • 22 Nov 2023 Mitsubishi Tanabe Pharma plans the phase III INSPIRE trial for Erythropoietic protoporphyria (In adolescents, In adults, In the elderly) in USA, Australia, Bulgaria, Czechia, France, Italy, the Netherlands, Poland, Spain and the UK (NCT06144840)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top